Antibody constructs for CD70 and CD3
US-10851170-B2 · Dec 1, 2020 · US
This page is not indexed by search engines while we improve data quality.
Amgen Res Munich Gmbh patents in 2020
Amgen Res Munich Gmbh was listed as an assignee on 17 patent publications in 2020.
| Metric | Value |
|---|---|
| Company | Amgen Res Munich Gmbh |
| Year | 2020 |
| Patents | 17 |
Patents
Representative publications for Amgen Res Munich Gmbh in 2020.
Cross-species-specific pscaxcd3, cd19xcd3, c-metxcd3, endosialinxcd3, epcamxcd3, igf-1rxcd3 or fapalphaxcd3 bispecific single chain antibody
US-2020362039-A1 · Nov 19, 2020 · US
Antibody constructs for dll3 and cd3
US-2020332002-A1 · Oct 22, 2020 · US
Low ph pharmaceutical composition comprising t cell engaging antibody constructs
US-2020332000-A1 · Oct 22, 2020 · US
PSMA and CD3 bispecific T cell engaging antibody constructs
US-10781264-B2 · Sep 22, 2020 · US
Top CPC classifications
Most common classification codes for Amgen Res Munich Gmbh in 2020.
| CPC | Patents |
|---|---|
| A61P35/00 | 16 |
| C07K16/2809 | 16 |
| C07K2317/31 | 16 |
| A61K2039/505 | 14 |
| C07K2317/622 | 13 |
Related pages
Navigate to parent entity pages.